Breaking News

Top 10 Pharma & Biopharma M&A Headlines of 2017

By: Kristin Brooks

Managing Editor, Contract Pharma

Mergers and acquisitions dominated the pharmaceutical and biopharmaceutical outsourced services industry in 2017. Additionally, 2017 saw numerous pharma/biopharma acquisitions to expand drug portfolios as well as to gain advanced drug development technologies. Leading global providers as well as smaller, specialty service providers were the target of acquisition efforts to gain/dominate market share. In line with increased outsourcing within the pharma/biopharma industry, demand for advanced technologies and global infrastructure, for increasingly complex drug products, namely biologics, has prompted a flurry of M&A this past year. –KB

Top M&A Headlines

Takeda Buys ARIAD for $5.2B

Fresenius Kabi Acquires Akorn in $4.3B Deal

Thermo Fisher Buys Patheon for $7.2B

Evotec to Pay $300M for Aptuit

Catalent to Acquire Cook Pharmica for $950M

Gilead to Acquire Kite Pharma


AMRI Bought for $922M

Lonza Acquires PharmaCell

Sanofi Buys Protein Sciences for $750M

3SBio Acquires Therapure for $290M

Further reading: CMO/CDMO Sector Mega-Mergers & Acquisitions; CMOs/CDMOs: Challenges and Opportunities

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters